Focal segmental glomerulosclerosis

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
6 Unique sponsors
4 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Receptor fusion protein 1 substance
Phase III: 2 Phase II: 4 Phase I: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Dimerix Bioscience Pty Limited Commercial
    REPAGERMANIUM
    2023-504597-37-00 7 countries 2022 n=95 Orphan
    Ended
  • Travere Therapeutics Inc. Commercial
    SPARSENTAN
    2023-505494-32-00 12 countries 2018 n=116 Orphan
    Ended

Phase II

4 trials
  • River 2 Renal Corp. Commercial
    R3R01
    2024-512964-73-00 4 countries 2023 n=20
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2024-511775-15-00 11 countries 2025 n=40
    Recruiting
  • Travere Therapeutics Inc. Commercial
    SPARSENTAN
    2023-505497-14-00 6 countries 2021 n=27 Orphan
    Recruiting
  • Vera Therapeutics Inc. Commercial
    ATACICEPT
    2024-518465-10-00 6 countries 2025 n=124 Orphan
    Recruiting

Phase I

1 trial
  • Walden Biosciences Inc. Commercial
    IMP not specified
    2024-516446-18-00 1 country n=84
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Travere Therapeutics Inc. Commercial 2 Phase II, Phase III 1
Walden Biosciences Inc. Commercial 1 Phase I 0
River 2 Renal Corp. Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 1
Vera Therapeutics Inc. Commercial 1 Phase II 1
Dimerix Bioscience Pty Limited Commercial 1 Phase III 0
New trials by year
2021
1
2022
1
2023
1
2025
2
← All indication landscapes